AliveCor and OMRON Announce Global Strategic Alliance

AliveCor, a leader in personal ECG products, and OMRON Healthcare, Co., Ltd., a global leader in personal heart health and wellness technology, today announced a global, strategic alliance that combines AliveCor’s ECG technology with industry-leading blood pressure devices from OMRON to better serve customers and expand access to remote patient care.

AliveCor advises this partnership aligns with global trends to deploy non-invasive remote monitoring devices to facilitate patient monitoring while reducing patient and healthcare provider contact during the current pandemic.

“At AliveCor, we are committed to providing life-saving cardiological services to those who need them most. The scope, scale, and strategic importance of this transaction are unprecedented in our corporate history,” said AliveCor CEO Priya Abani. “OMRON’s enormous R&D and distribution resources will bring AliveCor technology to more markets and more end-users than ever before.”

The COVID-19 pandemic underscores the importance of telemedicine in how we care for ourselves and loved ones. Those with chronic illnesses, including heart disease, are at higher risk of infection. AliveCor and OMRON serve this vulnerable population every day by allowing patients to send personal health data to physicians without leaving their homes. The companies’ ability to provide innovative, medical-grade technologies at home offers peace of mind to their users.

“The integration of these complementary technologies allows us to expand the heart health data we provide our customers and physician partners for a more complete picture of a patient’s heart health,” said Isao Ogino, president, and CEO of OMRON Healthcare.  “Our mission is ‘going for zero’ heart attacks and strokes. It is a lofty goal and we have committed to combining forces with like-minded partners to achieve it. OMRON has already made important strides with AliveCor to advance our mission and this expansion of that collaboration, including the development of remote patient monitoring services, is a valuable boost to our growing healthcare portfolio.”

The first technology collaboration between the two companies is the FDA cleared, award-winning OMRON Complete. Introduced in 2019, Complete is the first blood pressure monitor with ECG capability in a single device. The companies expect this product to be the first in a line of integrated ECG and blood pressure devices making home heart care more accessible to consumers than ever before.

The companies also announced today the closing of an equity investment by OMRON Corporation (OMRON Healthcare’s parent company) in AliveCor.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The ArthroFree system is the first FDA-cleared wireless camera for arthroscopy and general endoscopy, both areas of minimally invasive surgery. The system is designed to help surgeons work with aximum dexterity and focus.
The project, which was led by the University of Southern California, included large increases in representation among men of African, Hispanic and Asian ancestries, that were contributed in part by an ongoing collaboration between the U.S. Department of Veterans Affairs and DOE reports Argonne.
This innovative software turns smartphones into medical-grade stethoscopes, allowing people to capture, analyze, and share critical heart health data with medical personnel from the comfort of any location notes Sparrow BioAcoustics.
"Taewoong Medical becoming an Olympus group company is also a major milestone in our global growth strategy," said Henry Shin, CEO of STARmed. "We look forward to our products being made available to more patients through Olympus' global distribution network."
The company reports they have successfully met the six-month primary endpoint for the first-ever female patient implanted with the UroActive™ System, the first smart automated artificial urinary sphincter (AUS) to treat SUI.

By using this website you agree to accept Medical Device News Magazine Privacy Policy